Evidence map›Paper›PMID 36237272›Full record

ArticleTranslational cancer research2022

Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.

Jingyu Chen, Xueqi Zhao, Jinlin Wang, Fangfang Liu, Linli Zhang, Yuan Chen, Qian Chu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jingyu ChenDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Technology and Science, Wuhan, China.
Xueqi ZhaoDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Technology and Science, Wuhan, China.
Jinlin WangDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Technology and Science, Wuhan, China.
Fangfang LiuDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Technology and Science, Wuhan, China.
Linli ZhangDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Technology and Science, Wuhan, China.
Yuan ChenDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Technology and Science, Wuhan, China.
Qian ChuDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Technology and Science, Wuhan, China.
Tongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The resistance mechanisms to osimertinib encompass on-target molecular alterations, such as the well-known epidermal growth factor receptor ( Case Description: A 70-year-old Chinese woman without a smoking history presented with stage IV advanced LUAD harboring Conclusions: This case highlights the importance of NGS on repeated biopsy which could offer better treatment options.

Indexed as

brigatinib and cetuximabcase reportLung adenocarcinoma (LUAD)MET amplificationosimertinib

Identifiers

PMID36237272
PMCPMC9552262
OpenAlexW4287859531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.